intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 Centers for Disease Control and Prevention
In this study of 22 patients around the world treated with the gene therapy: Three of the nine patients with the most severe form of the disease stopped transfusions The need for blood transfusions was reduced by 73% overall in those patients 12 of the 13 patients with a less serious form of the disease no longer needed transfusions The researchers also said there were no safety concerns after the treatment in the short term
Rehydrate, recharge, and feel like yourself againin less than an hour
Your provider may not know how to properly manage the discomfort
The exact mechanism of fusion between autophagosomes and lysosomes is heavily regulated and has been thoroughly reviewed (81, 86, 90)
A Texas testing lab found 8% of submitted peptide products were contaminated , with purity in vials sold as BPC-157 ranging from 82% to 100%, and some vials not containing any BPC-157 at all
